Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 20, 2013
PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING SOUTH PLAINFIELD, NJ – June 20, 2013 – PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Additional Formats
Jun 03, 2013
PTC THERAPEUTICS APPOINTS SHANE KOVACS AS CHIEF FINANCIAL OFFICER SOUTH PLAINFIELD, NJ – June 3, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Additional Formats
May 16, 2013
PTC THERAPEUTICS, INC. FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING South Plainfield, NJ—May 16, 2013—PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to
Additional Formats
Apr 23, 2013
PTC THERAPEUTICS APPOINTS MARK ROTHERA AS CHIEF COMMERCIAL OFFICER SOUTH PLAINFIELD, NJ – April 23, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Additional Formats
Mar 07, 2013
-Funds to support Phase 3 confirmatory trials of ataluren-
Additional Formats
Dec 06, 2012
Enrollment for a Global Confirmatory Phase 3 Clinical Trial Planned for 1Q13
Additional Formats
Supporting Materials
Nov 06, 2012
SOUTH PLAINFIELD, NJ – November 6, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty
Additional Formats
Oct 22, 2012
SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue
Additional Formats
Sep 28, 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors SOUTH PLAINFIELD, NJ – September 28, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr.
Additional Formats
Jul 23, 2012
PTC THERAPEUTICS CLOSES $30 MILLION FINANCING   SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures,
Additional Formats